Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines

Oncology Reports

Volumn 29, Issue 2, 2013, Pages 555-562

  Zhuo, Lijuan ^a   Liu, Jingfeng ^a   Wang, Bin ^a   Gao, Meiqin ^a   Huang, Aimin ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Hepatocellular carcinoma; MiRNA microarray; Multidrug resistance; Real time PCR

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; MICRORNA; MICRORNA 146A; MICRORNA 146B 5P; MICRORNA 181A; MICRORNA 181D; MICRORNA 27B; MITOMYCIN; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; LIVER CELL CARCINOMA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; STRAIN DIFFERENCE; UPREGULATION;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CISPLATIN; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; LIVER NEOPLASMS; MICRORNAS; MITOMYCIN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; UP-REGULATION; VINCRISTINE;

EID: 84872816905     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2155     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Lee JO, Kim DY, Lim JH, et al: Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation. J Gastroenterol Hepatol 24: 800-805, 2009.
3. Tomuleasa C, Soritau O, Fischer-Fodor E, et al: Arsenic trioxide plus cisplatin/interferon alpha-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma. Hematol Oncol Stem Cell Ther 4: 60-66, 2011.
4. Walsh N, Larkin A, Kennedy S, et al: Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol 9: 6, 2009.
5. Shi H, Lu D, Shu Y, Shi W, Lu S and Wang K: Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S- transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Cancer Invest 26: 344-351, 2008. (Pubitemid 351601390)
6. Mansilla S, Rojas M, Bataller M, Priebe W and Portugal J: Circumvention of the multidrug-resistance protein (MRP-1) by an antitumor drug through specific inhibition of gene transcription in breast tumor cells. Biochem Pharmacol 73: 934-942, 2007.
7. Filomeni G, Turella P, Dupuis ML, et al: 6-(7-Nitro-2,1,3-benzoxadiazol- 4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1-mediated MDR in small cell lung cancer. Mol Cancer Ther 7: 371-379, 2008. (Pubitemid 351302530)
8. Ronaldson PT, Ashraf T and Bendayan R: Regulation of multidrug resistance protein 1 by tumor necrosis factor alpha in cultured glial cells: involvement of nuclear factor-kappaB and c-Jun N-terminal kinase signaling pathways. Mol Pharmacol 77: 644 - 659, 2010.
9. Liu B, Qu L and Tao H: Cyclooxygenase 2 up-regulates the effect of multidrug resistance. Cell Biol Int 34: 21-25, 2010.
10. Ma J, Dong C and Ji C: MicroRNA and drug resistance. Cancer Gene Ther 17: 523-531, 2010.
11. Feng DD, Zhang H, Zhang P, et al: Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med 15: 2164-2175, 2011.
12. Kovalchuk O, Filkowski J, Meservy J, et al: Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7: 2152-2159, 2008.
13. Liang Z, Wu H, Xia J, et al: Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 79: 817-824, 2010.
14. Xia L, Zhang D, Du R, et al: miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 123: 372-379, 2008. (Pubitemid 351842022)
15. Xu Y, Xia F, Ma L, et al: MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett 310: 160-169, 2011.
16. Zhao X, Yang L, Hu J and Ruan J: miR-138 might reverse multidrug resistance of leukemia cells. Leuk Res 34: 1078-1082, 2010.
17. Zhao X, Yang L and Hu J: Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 30: 55, 2011.
18. Zhu W, Shan X, Wang T, Shu Y and Liu P: miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 127: 2520-2529, 2010.
19. Akao Y, Noguchi S, Iio A, Kojima K, Takagi T and Naoe T: Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett 300: 197-204, 2011.
20. Bai H, Xu R, Cao Z, Wei D and Wang C: Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett 585: 402-408, 2011.
21. Yang H, Kong W, He L, et al: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68: 425-433, 2008. (Pubitemid 351380068)
22. Pan YZ, Morris ME and Yu AM: MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 75: 1374-1379, 2009.
23. Zhong X, Xiong M, Meng X and Gong R: Comparison of the multi-drug resistant human hepatocellular carcinoma cell line Bel-7402/ADM model established by three methods. J Exp Clin Cancer Res 29: 115, 2010.
24. Hummel R, Hussey DJ and Haier J: MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 46: 298-311, 2010.
25. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 111: 478-486, 2008.
26. Galluzzi L, Morselli E, Vitale I, et al: miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 70: 1793-1803, 2010.
27. Dai Y, Xie CH, Neis JP, Fan CY, Vural E and Spring PM: MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 33: 786-791, 2011.
28. Yu ZW, Zhong LP, Ji T, Zhang P, Chen WT and Zhang CP: MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 46: 317-322, 2010.
29. Boni V, Bitarte N, Cristobal I, et al: miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol Cancer Ther 9: 2265-2275, 2010.
30. Pogribny I P, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI and Kovalchuk O: Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 127: 1785-1794, 2010.
31. Chang CJ, Hsu CC, Chang CH, et al: Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer. Oncol Rep 26: 1003-1010, 2011.
32. Salter KH, Acharya CR, Walters KS, et al: An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS One 3: e1908, 2008.
33. Chen L, Li H, Han L, et al: Expression and function of miR-27b in human glioma. Oncol Rep 26: 1617-1621, 2011.
34. Ji J, Zhang J, Huang G, Qian J, Wang X and Mei S: Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett 583: 759-766, 2009.
35. Lee JJ, Drakaki A, Iliopoulos D and Struhl K: MiR-27b targets PPARgamma to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene 31: 3818-3825, 2012.
36. Wang Y, Rathinam R, Walch A and Alahari SK: ST14 (suppression of tumorigenicity 14) gene is a target for miR-27b, and the inhibitory effect of ST14 on cell growth is independent of miR-27b regulation. J Biol Chem 284: 23094-23106, 2009.
37. Bhaumik D, Scott GK, Schokrpur S, et al: MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. Aging (Albany, NY) 1: 402-411, 2009.
38. Chatzikyriakidou A, Voulgari P V, Georgiou I and Drosos AA: The role of microRNA-146a (miR-146a) and its target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility. Scand J Immunol 71: 382-385, 2010.
39. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J and Benz CC: Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 27: 5643-5647, 2008.
40. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS and Welch DR: Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 69: 1279-1283, 2009.
41. Kogo R, Mimori K, Tanaka F, Komune S and Mori M: Clinical significance of miR-146a in gastric cancer cases. Clin Cancer Res 17: 4277-4284, 2011.
42. Gao W, Yu Y, Cao H, et al: Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother 64: 399-408, 2010.
43. Schwind S, Maharry K, Radmacher MD, et al: Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 28: 5257-5264, 2010.
44. Wang XF, Shi ZM, Wang XR, et al: MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2. J Cancer Res Clin Oncol 138: 573-584, 2012.